

SEER*Stat Tools Webinar Series

From Data to Discovery: Free NCI resources to design and conduct data-driven projects and publish new research about childhood, adolescent, and young adult cancer

March 26, 2026

Panelists:

Johanna Goderre

Martin Krapcho

SURVEILLANCE RESEARCH PROGRAM

DIVISION OF CANCER CONTROL AND POPULATION SCIENCES

Panelists:

- **Johanna Goderre**

*National Childhood Cancer Registry (NCCR)
Technical Lead*

- **Martin Krapcho**

*Project Manager for NCCR*Explorer and
CONCORD*Explorer*

Moderator:

- **Anne-Michelle Noone**

*NCI Surveillance Research Program (SRP)
Mathematical Statistician*

Childhood Cancer Data Initiative (CCDI)

**SEER*Stat Tools:
From Data to Discovery: Free NCI resources to
design and conduct data-driven projects and
publish new research in CAYA cancer**

Johanna Goderre, MPH

Webinar

March 26, 2026

National Childhood Cancer Registry (NCCR)




What it is:

- A rapidly growing data resource for public health statistics
- Data collected about children, adolescents, and young adults (AYAs) with first cancer under age 40, regardless of where they receive care
- **29 NCCR registries**, represent 76% of the US population and report more than 1.7+ million cases 1995-2022
 - Plus, 12 registries through the [Virtual Pooled Registry](#) to confirm subsequent neoplasms

What it does:

- Enhances access to, and use of, detailed, longitudinal childhood cancer treatment and survivorship data matched to registry data
- Allows us to better understand the causes of cancer among children and AYAs and work to improve their outcomes and experiences

29 NCCR Registries



* VPR-linked Registries


Why is a national data sharing effort needed?

- Childhood cancer is **rare** (~16,000 new cases under age 20 each year in the US)
- Comprehensive view of the entire cancer journey: de-duplicate and link data from **multiple** healthcare providers at the national level



Travel for care
and life events

Subsequent
neoplasms



Late-effects
after treatment

Cancer Survivorship Brings New Challenges

“Brain fog is still quite a challenge for me. I can be quite forgetful especially misplacing things and when I get anxious or stressed my concentration is worse. This effects university, work, or even doing small things like driving.”

“Fatigue is still a big issue for me. Once we recover, we try to 'catch up' to the level that our friends have always been, forgetting that recovery can take a long while as there are many factors such as sleep, nutrition, and the complexity of our treatment that has such a massive impact.”

Tonorezos, ES et al. [PMC9082556](#) DOI: [10.1016/S0140-6736\(22\)00460-3](#)






(2 of 3) childhood cancer survivors will develop at least 1 late-onset therapy-related complication




(1 in 4) cases, the complication will be severe or life-threatening

- Organ function, growth and development, neurocognitive function, and additional cancers
 - Chronic symptoms of fatigue, dyssomnia, pain, hearing and vision impairments
 - Psychosocial consequences affect relationships, educational attainment, vocational and employment opportunities
 - Increased need for rehabilitation, screenings, and developmentally appropriate supports
- Potential benefits of CCDI and NCCR data:
 - Natural history of disease
 - Who is at risk and when
 - Adverse events
 - Severity and magnitude of symptoms, diagnoses, procedures, etc. in survivorship
 - Medications and treatments associated with increased risk
 - Potential supportive therapies
 - Guidelines analysis

Data from the Entire Cancer Journey and Across the Lifespan



Data from the Entire Cancer Journey and Across the Lifespan




All cancers in defined geographic areas with first cancer under age 40 1995-2021 (1.4M+ reported cancer cases for 1.3M+ persons)


Data from the Entire Cancer Journey and Across the Lifespan

Radiation dosage, outcomes:
2K+ persons with 8K+ records

Medical (286,274 persons with 62M+ records)
and pharmacy claims data (238,216 persons with 12M+ records)




NCCR Data Products & Access Types




NCCR*Explorer

Quick statistics on childhood and AYA prevalence and survival available to the public and researchers



NCCR Data in SEER*Stat


Statistics (frequencies, rates, trends, age-adjustment, survival, etc.) to study the impact of cancer on children and AYAs with a Research Plus application



NCCR Data Platform

View descriptive statistics and analyze individual-level registry data linked to longitudinal treatment use and outcomes with a Research Plus application

NCCR*Explorer




What it is:

- Interactive web application with incidence, survival, and prevalence cancer statistics
- Currently 28 registries, covers 74% of the US population, 1.7M+ reported cancers
- Children and AYAs ages 0-39 from 2001-2022 represented

What it does:


- Visualizes statistics in dynamic tables and plots based on user criteria
- Sorts data by patient demographics, age, and cancer type



nccrexplorer.ccdi.cancer.gov

datacatalog.ccdi.cancer.gov/dataset/CCDI-NCCR%20Exp

NCCR Data in SEER*Stat



What it is:

- Database in SEER*Stat from 26 NCCR registries
- 73% of US population and more than 1.6M+ reported cancer cases
- Children and AYAs ages 0-39 from 2001-2022 represented

What it does:

- Allows user-driven queries to develop frequency, rate, survival, and prevalence childhood cancer statistics

seer.cancer.gov/data-software/documentation/seerstat/nccr
datacatalog.ccdi.cancer.gov/dataset/CCDI-NCCR%20SEER*Stat

NCCR Data Platform

What it is:


- Web application that holds childhood cancer data from population-based cancer registries and other data partners
 - 20 SEER registries contribute data
 - 57% of US population; more than 1.4M+ reported cancers among individuals aged 0-39 at first diagnosis 1995-2022
- Data from registries, healthcare providers, and other sources are matched for same person and consolidated for analysis

What it does:

- Provides descriptive statistics for NCCR data linked to longitudinal treatment and outcome data
- Makes deidentified data easy to search, visualize, request, and analyze in a secure cloud system




Registered- and
Controlled-Access Data



nccrdatapatform.ccdi.cancer.gov/home

datacatalog.ccdi.cancer.gov/dataset/CCDI-NCCR_Data_Platform

NCCR integration with CCDI Ecosystem using the CCDI Participant Index (CPI)



- Cancer registries
- Claims
- Area-based measures
- Clinical information systems

- dbGaP PHS#s
- Kids First
- TARGET
- GENIE

NCI's Collection of Datasets for Pediatric and Adolescent and Young Adults Research

Collection Description

This collection contains a compilation of NIH authorized individual-level datasets on childhood cancers currently in dbGaP with various data use limitations (DULs) such as Pediatric Cancer Research without the NPU modifier. The collection has been created to streamline access to pediatric, and adolescent and young adults (AYA) cancer datasets under the purview of NCI DAC and other NIH IC DACs with permission and will include any additional authorized individual-level datasets as they become available. To request access to this study collection, select phs003964 in the dbGaP Authorized Access System.

Authorized Access

Note: When requesting for access to this Collection in the [dbGaP Authorized Access Portal](#), go to **Study lookup** and type in **phs003964** (not including the version number, v#, and participant set number, p#). Do not use this Collection accession for acknowledgements. Rather, acknowledge the phs accession numbers including v# and p# for the specific studies used from this Collection.

- **Data access provided by:** [dbGaP Authorized Access](#)
- **Release Date:** 2026-02-10
- [Data Use Certification Requirements \(DUC\)](#)
- **Public Posting of Genomic Summary Results:** Restricted
- **Data Use Limitations**

| Consent code | Consent group | Consent abbreviation | Is IRB required? | Data Access Committee |
|--------------|---|----------------------|------------------|--|
| 1 | Disease-Specific (Pediatric Cancer Research, PUB, MDS, GSO) ? | DS-PEDCR-PUB-MDS-GSO | No | NCI DAC (NCIDAC@mail.nih.gov) |

- [List of Components](#) downloadable from [Authorized Access](#)

Studies Included in Collection

Disease-Specific (Pediatric Cancer Research, PUB, MDS, GSO) (DS-PEDCR-PUB-MDS-GSO) n=68 studies

* Counts are unavailable for summary level data, such as analyses, or data stored in an external data source.

| Study Accession | Study Name | Consent Group | Subject Count | Sample Count | SSTR |
|----------------------------------|--|---|---------------|-----------------------|----------------------|
| phs000178.v11.p8 | The Cancer Genome Atlas (TCGA) | General Research Use (GRU) | 11429 | 11467 | SSTR |
| phs000218.v26.p8 | National Cancer Institute (NCI) TARGET: Therapeutically Applicable Research to Generate Effective Treatments | Disease-Specific (Pediatric Cancer Research) (DS-PEDCR) | 6363 | 13179 | SSTR |
| phs000409.v1.p1 | Sequencing of Medulloblastoma | General Research Use (GRU) | 93 | 306 | SSTR |

https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/collection.cgi?study_id=phs003964.v2.p2

[phs002517.v4.p2](#) Childhood Cancer Data Initiative (CCDI): Molecular Characterization across Pediatric Brain Tumors and Other Solid and Hematologic Malignancies for Research, Diagnostic, and Precision Medicine
General Research Use (GRU) 3960 [9082](#) [SSTR](#)

[phs002790.v9.p3](#) Childhood Cancer Data Initiative (CCDI): Molecular Characterization Initiative
General Research Use (GRU) 5516 [15622](#) [SSTR](#)



Benefits to Researchers

- Single process to explore, visualize, and request population-based registry and real-world longitudinal data that describes a patient's entire cancer journey
- Efficient national-level linkages from multiple healthcare providers and time points ready for analysis
- Linkage to dbGaP and CCDI data
- Data updated annually for all children, adolescents and young adults (AYA) with all types of cancers to support new and ongoing studies
 - Large pool of data to support emerging research questions


Access for Data Platform

- If you are outside NIH:
 - Your institution must sponsor your account in eRA Commons and you link that same institutional email account to Login.gov
 - Submit for a SEER Research Plus account with ORCID, Signing Official's name, sign the DUA, etc.
- Once approved, you can login to the Data Platform
 - Browse data, define cohort and data sources needed, secure IRB determination, and submit a data request to the NCI Data Access Committee

Researchers receive data, codebook, and import scripts

Synthetic Data:


| Data Request Patient ID | Cohort Def | claimDiagn | claimDiagn | monthsFrom |
|-------------------------|------------|------------|------------|------------|
| 8cbcb46674c9-05131143 | Yes | 6253 | 807 | 49 |
| 8cbcb46674c9-94245110 | Yes | C499 | 819 | 49 |
| 8cbcb46674c9-49605258 | Yes | Q038 | 825 | 40 |
| 8cbcb46674c9-22986066 | Yes | M40202 | 819 | 32 |
| 8cbcb46674c9-15999101 | Yes | V7232 | 811 | 49 |
| 8cbcb46674c9-50995416 | Yes | 1719 | 806 | 49 |
| 8cbcb46674c9-25844183 | Yes | 28803 | 820 | 29 |
| 8cbcb46674c9-07484427 | Yes | 3669 | 809 | 9999 |
| 8cbcb46674c9-31081906 | Yes | M25559 | 816 | 49 |
| 8cbcb46674c9-43903852 | Yes | 7062 | 802 | 49 |



Sequence number for diagnoses codes that occurred on multiple claims within the same month.<p>Claims are deduplicated over the patient ID, claim service date and claim diagnosis code. Records with the same diagnosis code occurring on different dates but in the same month will be assigned a different sequence number.

| | | | | | | |
|----------------------------------|---|--|--|-----|---------|----------|
| claimDiagnosisCodeSequence | Claim Diagnosis Code Sequence Number | | | 3 | numeric | 801-831 |
| monthsFromIndexDxToDiagnosisCode | Months From Index Cancer Diagnosis to Service Date of Claim | Number of months from the index cancer diagnosis to service date of claim for the diagnosis code | | 3-4 | numeric | -999-999 |
| monthsFromIndexDxToDiagnosisCode | Months From Index Cancer Diagnosis to Service Date of Claim | Number of months from the index cancer diagnosis to service date of claim for the diagnosis code | | 3-4 | numeric | 9999 |


Data from the Entire Cancer Journey and Across the Lifespan






Person
XG7N2K

Data Source: Consolidated Tumor Cases (CTC)



| | Tumor Rec # | Tumor Order | Year Dx | Index Ca | # Mo. Index Ca to Tumor |
|--------|-------------|-------------|---------|----------|-------------------------|
| XG7N2K | 02 | 2 | 2011 | 0 | 12 |
| XG7N2K | 01 | 1 | 2010 | 1 | 0 |
| XG7N2K | 03 | 3 | 2013 | 0 | 36 |

Data Source: Consolidated Tumor Cases (CTC)



| Tumor Rec # | Tumor Order | Year Dx | Index Ca | # Mo. Ca to Tumor | Index |
|-------------|-------------|---------|----------|-------------------|-------|
| 02 | 2 | 2011 | 0 | 12 | X |
| 01 | 1 | 2010 | 1 | 0 | |
| 03 | 3 | 2013 | 0 | 36 | X |

Person
XG7N2K

Data Source: Area-Based Measures (ABM)*

* ABM is only at time of index cancer

| | Yost Q | Urban Rural Indicator Codes (URIC) |
|--------|--------|------------------------------------|
| XG7N2K | 2 | 2 |


Procedures

Mo. Index Ca
to Procedure

Procedure
code

| | | |
|--------|---|-------|
| XG7N2K | 0 | 80053 |
|--------|---|-------|

Comprehensive Metabolic Panel (CMP)



Same month as
index cancer

Pharmacy Claims

Mo. Index Ca
to Dispense

Non-proprietary
name

| | | |
|--------|---|------------|
| XG7N2K | 0 | Prednisone |
|--------|---|------------|

| | | |
|--------|---|------------------|
| XG7N2K | 0 | Cyclophosphamide |
|--------|---|------------------|

Procedures

Mo. Index Ca
to Procedure

Procedure
code


| | | |
|--------|-----|-------|
| XG7N2K | -25 | A0425 |
| XG7N2K | 0 | 80053 |
| XG7N2K | 39 | 97112 |

Ambulance fee




Before index
cancer

Comprehensive Metabolic Panel (CMP)



Same month as
index cancer

Neuromuscular reeducation therapy



Person
XG79N2K

After 3rd cancer

Pharmacy Claims


Mo. Index Ca
to Dispense

Non-proprietary
name

| | | |
|--------|-----|------------------|
| XG7N2K | 0 | Prednisone |
| XG7N2K | 0 | Cyclophosphamide |
| XG7N2K | 110 | Fluticasone |




Telling the story from data




The NCCR Data Platform has extensive data on the longitudinal cancer journey. Researchers can come back and ask new questions for new research projects.

Project 1: Exposure to specific medications and experience of cardiac toxicities



Project 1: Exposure to specific medications and experience of cardiac toxicities






Project 2: Exposure to radiotherapy and experience of additional cancer




Project 2: Exposure to radiotherapy and experience of additional cancer






Project 3: Differences in survival by age and by diagnosis




Project 3: Differences in survival by age and by diagnosis





Project 4: Compare ED visits by upfront treatment intensity



Project 4: Compare ED visits by upfront treatment intensity




This page provides examples, tips, and guidelines for analyzing cohort data downloaded from the National Childhood Cancer Registry Data Platform.

What kind of research is possible with NCCR data?

The table below provides example research projects that illustrate the kind of questions you can explore with NCCR's advanced data linkages. Each example includes a link to the shared cohort associated with that research project. You can save these cohorts to your NCCR account if you wish to review their data or use them for your own research.

| Research Question | Description | Research Plan | Record Counts | Cohort Link |
|---|--|--|--|-----------------------------|
| Treatment intensity by number of interventions | Evaluation of survivorship in patients with high versus low treatment intensity, determined by the number of interventions documented in medical and pharmacy claims datasets. | This cohort includes patients who received any linked pharmacy claims data. Patients who did not receive any confirmed chemotherapy claims were excluded. All datasets are included in this cohort to expand the ability to conduct adequate subgroup analyses. | <ul style="list-style-type: none"> 88,479 patients 101,671 tumors | View Cohort |
| Comparison of the rate of emergency department visits in high treatment intensity patients compared to low treatment intensity. | Evaluation of the rate of emergency department visits identified by medical claims procedure codes in patients receiving high treatment intensity compared to low treatment intensity. | This cohort includes patients who received any linked pharmacy claims data. Patients who did not receive any confirmed chemotherapy claims were excluded. All datasets are included in this cohort to expand the ability to conduct adequate subgroup analyses. To identify the emergency department visits, we recommend using the medical claims procedure dataset and further filtering the cohort to isolate emergency department events. Example CPT codes include codes 99281-99285, but additional HCPCS, ICD9 or ICD10 codes could be included to best test the researcher's hypothesis. | <ul style="list-style-type: none"> 88,479 patients 101,671 tumors | View Cohort |
| Evaluation of cardiovascular events after anthracycline therapy. | Evaluation of documented cardiovascular events in pharmacy and medical claims datasets in patients receiving | This cohort includes patients who received any linked pharmacy claims data. Patients who did not receive any confirmed chemotherapy claims were excluded. To identify cardiotoxic chemotherapies, you will need to filter by the CanMED major, minor, or proprietary name fields to isolate a cohort with confirmed | <ul style="list-style-type: none"> 137,793 patients 158,891 tumors | View Cohort |



Volume 117, Issue 9
September 2025

Article Contents

...

JOURNAL ARTICLE

Enrollment in Children's Oncology Group's clinical trials: population-based linkage with the National Childhood Cancer Registry [Get access >](#)

Philip J Lupo, PhD ✉, David A Siegel, MD, MPH, Nicola C Schussler, BS, Todd A Alonzo, PhD, Suzanne Adams, ODS-C, BS, David Angelaszek, MS, Shanthala Basavappa, MS, Tiffany M Chambers, MPH, Linda Coyle, BS, Eric Durbin, DrPH, MS ... [Show more](#)

JNCI: *Journal of the National Cancer Institute*, Volume 117, Issue 9, September 2025, Pages 1868–1874, <https://doi.org/10.1093/jnci/djaf134>

Published: 14 June 2025 [Article history >](#)



Pediatric Hematology and Oncology >

Volume 42, 2025 - [Issue 1](#)

Enter keywords, authors, DOI, etc

[Submit an article](#)

[Journal homepage](#)

188

Views

4

CrossRef citations to date

0

Altmetric

Research Articles

Temporal trends in pediatric cancer mortality: rare cancers lag behind more common cancers

Brian R. Englum ✉, Shalini Sahoo, Theodore W. Laetsch, Gregory M. Tiao, Minerva Mayorga-Carlin, Hilary Hayssen, ...[show all](#)

Pages 1–13 | Received 03 Oct 2023, Accepted 02 Oct 2024, Published online: 24 Oct 2024

[Cite this article](#) <https://doi.org/10.1080/08880018.2024.2413643>



Article Navigation

JOURNAL ARTICLE

Making the case for an International Childhood Cancer Data Partnership ^{FREE}

Gonçalo Forjaz, DVM, MSc, Betsy Kohler, MPH, Michel P Coleman, MD, Eva Steliarova-Foucher, PhD, Serban Negoita, MD, DrPH ✉, Jaime M Guidry Auvil, PhD, Fernanda Silva Michels, MSc, PhD, Johanna Goderre, MPH, Charles Wiggins, PhD, Eric B Durbin, DrPH ... [Show more](#)

JNCI: *Journal of the National Cancer Institute*, Volume 117, Issue 8, August 2025, Pages 1539–1546, <https://doi.org/10.1093/jnci/djaf003>

Published: 12 January 2025 [Article history >](#)

Pediatric Blood & Cancer

LETTER TO THE EDITOR

Declining Incidence of Childhood Cancers: An Updated Analysis of the National Childhood Cancer Registry Data (2018–2021)

[Jason Semprini](#) ✉

First published: 04 January 2025 | <https://doi.org/10.1002/psc.31506> |




Volume 72, Issue 3
March 2025
e31506

Advertisement

<https://nccrexplorer.ccdi.cancer.gov/data-products.html>

CCDI Tools Serve All Types of Users



Administrative Supplements in FY26

<https://cancercontrol.cancer.gov/funding/dccps-topics-of-interest-for-administrative-supplements-in-fy26>

26 topics of interest, including

- NCCR data platform for AYA and early-onset cancers: leverages existing data on the NCCR data platform to further understanding of diagnosis, treatment, outcomes, health disparities, survivorship, risk, and outcomes of cancers diagnosed among adolescent and young adult and early-onset cancers.
- Standardized methods for EHR and RWD harmonization: fosters the adaption or development of standardized protocols or methods to enable the extraction and/or harmonization of data from diverse sources of electronic health records (EHRs) and other real-world data (RWD) in the cancer research domain. These efforts will support the systematic capture of treatment exposures, comorbidities, clinical outcomes, and other key variables to enhance data quality, comparability, and reproducibility across studies.

Thank you!



**NATIONAL
CANCER
INSTITUTE**

cancer.gov

cancer.gov/espanol

CCDI Resources

CCDI Platforms and Tools

- [CCDI Hub](https://ccdi.cancer.gov): ccdi.cancer.gov
 - [CCDI Hub Explore Dashboard](https://ccdi.cancer.gov/explore): ccdi.cancer.gov/explore
- [Childhood Cancer Clinical Data Commons](https://clinicalcommons.ccdi.cancer.gov): clinicalcommons.ccdi.cancer.gov
- [cBioPortal Cancer Data Explorer](https://cbioportal.ccdi.cancer.gov)
<https://cbioportal.ccdi.cancer.gov>
- [Childhood Cancer Data Catalog](https://datacatalog.ccdi.cancer.gov): datacatalog.ccdi.cancer.gov
- [Molecular Targets Platform](https://moleculartargets.ccdi.cancer.gov): moleculartargets.ccdi.cancer.gov
- [National Childhood Cancer Registry](https://nccrexplorer.ccdi.cancer.gov/data-products.html): nccrexplorer.ccdi.cancer.gov/data-products.html

APIs

- [CCDI Data Federation Resource](https://ccdi.cancer.gov/data-federation-resource): ccdi.cancer.gov/data-federation-resource
- [CCDI Participant Index](https://ccdi.cancer.gov/ccdi-participant-index): ccdi.cancer.gov/ccdi-participant-index

- [CCDI Tools](https://ccdi.cancer.gov/tools) (including [MCI_JSON2TSV](https://ccdi.cancer.gov/tools/mci_json2tsv)) : ccdi.cancer.gov/tools
MCI_JSON2TSV is a Python-based command-line interface that converts MCI de-identified clinical report and clinical data files submitted in JSON format into tab-separated values (TSV) files.

Tutorials and Guides

- [Hub Explore Dashboard User Guide and Access Instructions](https://ccdi.cancer.gov/user-guide.pdf): ccdi.cancer.gov/user-guide.pdf
- [CCDI Data Submission Guide](https://ccdi.cancer.gov/Submission_Guide.pdf): ccdi.cancer.gov/Submission_Guide.pdf
- [Hub Explore Dashboard Tutorial Video](https://youtu.be/Eu8y1GDTszU): youtu.be/Eu8y1GDTszU
- [How to Apply for dbGaP Controlled Access Video](https://youtube.com/watch?v=m0xp_cCO7kA): youtube.com/watch?v=m0xp_cCO7kA

How You Can Help Communicate About CCDI

Use our hashtag:

[#Data4ChildhoodCancer](#)

Subscribe to our monthly newsletter at:

cancer.gov/CCDI

Questions? Email us at:

NCIChildhoodCancerDataInitiative@mail.nih.gov



NCCR*Explorer and NCCR Data in SEER*Stat

Overview of NCCR cancer statistics available on the NCCR website and in the SEER*Stat application.

Marty Krapcho

Information Management Services (IMS) Inc.

Goals

- Provide an overview of the NCCR*Explorer web application, SEER*Stat and the NCCR Database available in SEER*Stat.
- Highlight features and functionalities built into the applications.
- Demonstrate practical applications of these tools.
- Show how NCCR data in SEER*Stat can be used to expand on statistics found in NCCR*Explorer

NCCR*Explorer

<https://nccrexplorer.ccdi.cancer.gov/>

- Developed under the NCI Childhood Cancer Data Initiative (CCDI)
- Free public-use web application providing graphs and data tables for childhood cancer statistics
- Pre-generated childhood cancer diagnosis and survival estimates from the annual National Childhood Cancer Registry (NCCR) data submission
- Updated Annually to reflect latest NCCR data submission
- Cancer site coding based on ICCC Recode Third Edition ICD-O-3/IARC 2017

NCCR*Explorer Demo

SEER*Stat

<https://seer.cancer.gov/seerstat/>

- Free desktop application for Windows PCs. Access to SEER Data use within the application does require a data request.
- Provides a convenient, intuitive mechanism for the analysis of SEER and other cancer-related databases.
- Step-by-step training tutorials and on-line help system are available on SEER website.

NCCR Data in SEER*Stat

<https://seer.cancer.gov/data/access.html>

- Developed under the NCI Childhood Cancer Data Initiative (CCDI)
- Available with the SEER Research Plus Data Sets. Access requires user authentication with an eRA Commons or an HHS account.
- Less coverage of U.S. population than NCCR*Explorer.
- Provides greater flexibility in defining analyses.
Year ranges, age ranges, survival time intervals can be set by the user.
Cancer sites can be defined by primary site, histology, behavior and additional fields.

NCCR Data in SEER*Stat Demo

Product Overview and Access

| | NCCR*Explorer | NCCR Data in SEER*Stat |
|---------------------|--|--|
| What's Included | Precalculated incidence, survival, and prevalence statistics | Frequencies and rates (e.g., trends, age-adjusted rates) and Survival statistics |
| Where to Find | NCCR*Explorer Website https://nccrexplorer.ccdi.cancer.gov | SEER Web site https://seer.cancer.gov/data/access.html |
| Access Requirements | Publicly available, open access web application (No login required) | Requires a SEER Research Plus application and authentication with an eRA Commons or HHS account |
| Data Use Agreements | Not required | Required |

Data Source and Demographics

| | NCCR*Explorer | NCCR Data in SEER*Stat |
|--------------------------|----------------------------------|----------------------------------|
| Participating Registries | 29 NCCR Registries | 25 States and Seattle |
| Population Coverage | 76% of U.S. ages 0-39 population | 73% of U.S. ages 0-39 population |
| Ages | 0-39 | 0-39 |
| Years of Diagnosis | 2001-2022 | 2001-2022 |

Additional Explorer Resources

- Concord Explorer

Global Survival estimates for childhood cancer groups using data from the CONCORD Programme.

<https://seer.cancer.gov/statistics-network/concord/>

- SEER*Explorer

SEER cancer statistics using the SEER primary site recode. Includes basic childhood cancer age groups.

<https://seer.cancer.gov/statistics-network/explorer/>

- CiNA Explorer

NAACCR cancer statistics : <https://apps.naaccr.org/explorer/>

SEER*Stat Resources

<https://seer.cancer.gov/seerstat/>

- Request Access to SEER Data
- Download SEER*Stat Software
- SEER*Stat Tutorials
Step-by-step instructions for using SEER*Stat to calculate statistics, view database values, and export results.
- Online Help System and SEER*Stat Technical Support

Acknowledgements

- National Cancer Institute (NCI)
- The Surveillance, Epidemiology, and End Results (SEER) Program
- NCCR Cancer Registries
- Information Management Services, Inc.

Thank You!

<https://seer.cancer.gov/news/seerstat-webinars.html>



NATIONAL
CANCER
INSTITUTE

cancer.gov

cancer.gov/espanol

SURVEILLANCE RESEARCH PROGRAM

DIVISION OF CANCER CONTROL AND POPULATION SCIENCES